adenine has been researched along with Chronic Illness in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The frequency of homozygocity for the rare allele of the beta-fibrinogen gene (H2H2) was 13% for the periodontitis patients and 3% for the control group (P = 0." | 7.72 | Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis. ( De Nardin, E; Genco, RJ; Sahingur, SE; Sharma, A, 2003) |
| "Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment." | 7.72 | Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004) |
| "We recently identified a single R117H mutation in the cationic trypsinogen gene in several kindreds with an inherited form of acute and chronic pancreatitis (HP1), providing strong evidence that trypsin plays a central role in premature zymogen activation and pancreatitis." | 7.69 | Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. ( Aston, CE; Ehrlich, GD; Furey, W; Gabbaizedeh, D; Gates, LK; Gorry, MC; Preston, RA; Ulrich, C; Whitcomb, DC; Zhang, Y, 1997) |
| " Folic acid-induced acute kidney injury increased calvaria FGF23 mRNA and serum FGF23 and parathyroid hormone (PTH) levels at 6 h." | 3.83 | The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. ( Durlacher, K; Hassan, A; Levi, R; Naveh-Many, T; Silver, J, 2016) |
| "The adenine-treated animals exhibited marked azotemia, impaired urinary concentrating capacity, intense tubular and glomerular damage, interstitial inflammation and fibrosis." | 3.79 | Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. ( Aminzadeh, MA; Nicholas, SB; Norris, KC; Vaziri, ND, 2013) |
| "After adenine dosing, significant hyperphosphatemia, hypocalcemia and secondary hyperparathyroidism (2HPT) were observed during the experimental period of 15 weeks." | 3.75 | Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. ( Fujimori, A; Fukushima, S; Itoh, H; Mizukami, K; Nara, H; Okada, M; Sanagi, M; Takakura, K; Terai, K, 2009) |
| "The frequency of homozygocity for the rare allele of the beta-fibrinogen gene (H2H2) was 13% for the periodontitis patients and 3% for the control group (P = 0." | 3.72 | Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis. ( De Nardin, E; Genco, RJ; Sahingur, SE; Sharma, A, 2003) |
| "Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation." | 3.72 | Tenofovir therapy for lamivudine resistance following liver transplantation. ( Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG, 2004) |
| "Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment." | 3.72 | Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004) |
| "We recently identified a single R117H mutation in the cationic trypsinogen gene in several kindreds with an inherited form of acute and chronic pancreatitis (HP1), providing strong evidence that trypsin plays a central role in premature zymogen activation and pancreatitis." | 3.69 | Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. ( Aston, CE; Ehrlich, GD; Furey, W; Gabbaizedeh, D; Gates, LK; Gorry, MC; Preston, RA; Ulrich, C; Whitcomb, DC; Zhang, Y, 1997) |
| "Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK." | 2.94 | ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. ( Brown, JR; Cohen, A; Eichhorst, BF; Hilger, J; Hillmen, P; Huang, J; Lamanna, N; O'Brien, SM; Qiu, L; Salmi, T; Tam, CS; Wu, K, 2020) |
| "Acute renal failure is common in HIV-infected patients and is associated with acute infection and medication-related nephrotoxicity." | 2.44 | HIV-1 infection and the kidney: an evolving challenge in HIV medicine. ( de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA, 2007) |
| "Moreover, treatment of bronchiolitis obliterans syndrome demonstrates heterogeneity in applied therapeutic options and sequence because of a lack of controlled data and different conclusions from already existing evidence." | 1.51 | Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. ( Ayuk, F; Ditschkowski, M; Gerbitz, A; Greinix, H; Halter, J; Hilgendorf, I; Holler, E; Jedlickova, Z; Klein, S; Kobbe, G; Lawitschka, A; Middeke, JM; Schäfer-Eckart, K; Stadler, M; Stelljes, M; Wagner-Drouet, E; Winkler, J; Wolff, D; Zeiser, R, 2019) |
| "Adenine-fed rats exhibited renal failure, ectopic calcification and altered serum parameters, including elevated levels of serum Pi, Cr, PTH and BUN." | 1.36 | Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications. ( Ikeda, R; Imai, Y; Maruyama, W; Mizoguchi, K, 2010) |
| "Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA." | 1.36 | The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. ( Antonioli, L; Awwad, O; Blandizzi, C; Colucci, R; Da Settimo, F; Duranti, E; Fornai, M; Ghisu, N; La Motta, C; Natale, G; Tuccori, M; Virdis, A, 2010) |
| "Secondary hyperparathyroidism is characterized by increased parathyroid hormone (PTH) mRNA stability that leads to increased PTH mRNA and serum PTH levels." | 1.35 | Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. ( Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J, 2009) |
| "Severe forms of periodontitis are suggested to have a genetic basis." | 1.32 | Association of the -1087 IL 10 gene polymorphism with severe chronic periodontitis in Swedish Caucasians. ( Berglundh, T; Donati, M; Hahn-Zoric, M; Hanson, LA; Padyukov, L, 2003) |
| "Periodontitis is an inflammatory disease that leads to irreversible attachment loss, bone destruction and eventually tooth loss." | 1.32 | Polymorphisms in the +252(A/G) lymphotoxin-alpha and the -308(A/G) tumor necrosis factor-alpha genes and susceptibility to chronic periodontitis in a Czech population. ( Buckova, D; Fassmann, A; Holla, LI; Vanek, J; Vasku, A; Znojil, V, 2003) |
| "Bilateral mechanical hyperalgesia of the paw was induced by administering two injections of acidic saline, 5 d apart, into the gastrocnemius muscle of male Sprague Dawley rats." | 1.32 | Phosphorylation of CREB and mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections. ( Hoeger-Bement, MK; Sluka, KA, 2003) |
| "We present a case in which acute renal failure developed after therapy with tenofovir DF in a patient with HIV and stable chronic kidney disease." | 1.31 | Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. ( Coca, S; Perazella, MA, 2002) |
| "Adefovir dipivoxil is a prodrug of adefovir designed to enhance its oral bioavailability." | 1.31 | Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. ( Brown, C; Cullen, JM; Cundy, KC; Eisenberg, EJ; Gibbs, C; Li, DH; Toole, J; Wolfe, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.92) | 18.7374 |
| 1990's | 5 (9.62) | 18.2507 |
| 2000's | 20 (38.46) | 29.6817 |
| 2010's | 21 (40.38) | 24.3611 |
| 2020's | 5 (9.62) | 2.80 |
| Authors | Studies |
|---|---|
| Hillmen, P | 1 |
| Brown, JR | 1 |
| Eichhorst, BF | 1 |
| Lamanna, N | 1 |
| O'Brien, SM | 1 |
| Qiu, L | 1 |
| Salmi, T | 1 |
| Hilger, J | 1 |
| Wu, K | 1 |
| Cohen, A | 1 |
| Huang, J | 1 |
| Tam, CS | 1 |
| Gonzalez, RM | 1 |
| Pidala, J | 1 |
| Limaye, S | 1 |
| Limaye, V | 1 |
| Kaloyannidis, P | 1 |
| Ayyad, A | 1 |
| Bahaliwah, Z | 1 |
| Blowi, B | 1 |
| Alanazi, W | 1 |
| Al Shammasi, Z | 1 |
| Elsoudi, H | 1 |
| Ibrahim, I | 1 |
| Al Hashmi, H | 1 |
| Doki, N | 1 |
| Toyosaki, M | 1 |
| Shiratori, S | 1 |
| Osumi, T | 1 |
| Okada, M | 2 |
| Kawakita, T | 1 |
| Sawa, M | 1 |
| Ishikawa, T | 1 |
| Ueda, Y | 1 |
| Yoshinari, N | 1 |
| Nakahara, S | 1 |
| Miklos, D | 2 |
| Cutler, CS | 1 |
| Arora, M | 2 |
| Waller, EK | 2 |
| Jagasia, M | 1 |
| Pusic, I | 2 |
| Flowers, ME | 1 |
| Logan, AC | 3 |
| Nakamura, R | 2 |
| Blazar, BR | 2 |
| Li, Y | 1 |
| Chang, S | 2 |
| Lal, I | 1 |
| Dubovsky, J | 1 |
| James, DF | 1 |
| Styles, L | 2 |
| Jaglowski, S | 2 |
| Rahmat, LT | 1 |
| Jaglowski, SM | 1 |
| Boudin, L | 1 |
| Patient, M | 1 |
| Tsitsi Nding Tsogou, P | 1 |
| Roméo, E | 1 |
| Bladé, JS | 1 |
| de Jauréguiberry, JP | 1 |
| Wolff, D | 1 |
| Hilgendorf, I | 2 |
| Wagner-Drouet, E | 1 |
| Jedlickova, Z | 1 |
| Ayuk, F | 1 |
| Zeiser, R | 1 |
| Schäfer-Eckart, K | 1 |
| Gerbitz, A | 1 |
| Stadler, M | 1 |
| Klein, S | 1 |
| Middeke, JM | 1 |
| Lawitschka, A | 1 |
| Winkler, J | 1 |
| Halter, J | 1 |
| Holler, E | 1 |
| Kobbe, G | 1 |
| Stelljes, M | 1 |
| Ditschkowski, M | 1 |
| Greinix, H | 1 |
| Cutler, C | 1 |
| Jagasia, MH | 1 |
| Flowers, MED | 1 |
| Clow, F | 1 |
| Lal, ID | 1 |
| Aminzadeh, MA | 1 |
| Nicholas, SB | 1 |
| Norris, KC | 1 |
| Vaziri, ND | 1 |
| Czech, B | 1 |
| Dettmer, K | 1 |
| Valletta, D | 1 |
| Saugspier, M | 1 |
| Koch, A | 1 |
| Stevens, AP | 1 |
| Thasler, WE | 1 |
| Müller, M | 1 |
| Oefner, PJ | 1 |
| Bosserhoff, AK | 1 |
| Hellerbrand, C | 1 |
| Bagcchi, S | 1 |
| Rozovski, U | 1 |
| Benjamini, O | 1 |
| Jain, P | 1 |
| Thompson, PA | 1 |
| Wierda, WG | 1 |
| O'Brien, S | 1 |
| Burger, JA | 1 |
| Ferrajoli, A | 1 |
| Faderl, S | 1 |
| Shpall, E | 1 |
| Hosing, C | 1 |
| Khouri, IF | 1 |
| Champlin, R | 1 |
| Keating, MJ | 1 |
| Estrov, Z | 1 |
| Hassan, A | 1 |
| Durlacher, K | 1 |
| Silver, J | 3 |
| Naveh-Many, T | 3 |
| Levi, R | 1 |
| Lo, YL | 1 |
| See, SJ | 1 |
| Tan, CK | 1 |
| Nechama, M | 1 |
| Ben-Dov, IZ | 2 |
| Terai, K | 1 |
| Nara, H | 1 |
| Takakura, K | 1 |
| Mizukami, K | 1 |
| Sanagi, M | 1 |
| Fukushima, S | 1 |
| Fujimori, A | 1 |
| Itoh, H | 1 |
| Galitzer, H | 1 |
| Ikeda, R | 1 |
| Imai, Y | 1 |
| Maruyama, W | 1 |
| Mizoguchi, K | 1 |
| Ali, BH | 1 |
| Al-Salam, S | 1 |
| Al Husseni, I | 1 |
| Kayed, RR | 1 |
| Al-Masroori, N | 1 |
| Al-Harthi, T | 1 |
| Al Zaabi, M | 1 |
| Nemmar, A | 1 |
| Antonioli, L | 1 |
| Fornai, M | 1 |
| Colucci, R | 1 |
| Awwad, O | 1 |
| Ghisu, N | 1 |
| Tuccori, M | 1 |
| Da Settimo, F | 1 |
| La Motta, C | 1 |
| Natale, G | 1 |
| Duranti, E | 1 |
| Virdis, A | 1 |
| Blandizzi, C | 1 |
| Langer, S | 1 |
| Kokozidou, M | 1 |
| Heiss, C | 1 |
| Kranz, J | 1 |
| Kessler, T | 1 |
| Paulus, N | 1 |
| Krüger, T | 1 |
| Jacobs, MJ | 1 |
| Lente, C | 1 |
| Koeppel, TA | 1 |
| Loebermann, M | 1 |
| Borchert, K | 1 |
| Junghanss, C | 1 |
| Freund, M | 1 |
| Schmitt, M | 1 |
| Gracey, D | 1 |
| Post, J | 1 |
| MacLeod, C | 1 |
| McKenzie, P | 1 |
| Islam, FM | 1 |
| Wu, J | 1 |
| Jansson, J | 1 |
| Wilson, DP | 1 |
| Ying, H | 1 |
| Fu, H | 1 |
| Rose, ML | 1 |
| McCormack, AM | 1 |
| Sarathchandra, P | 1 |
| Okkenhaug, K | 1 |
| Marelli-Berg, FM | 1 |
| Leonard, JP | 1 |
| Coca, S | 1 |
| Perazella, MA | 1 |
| Berglundh, T | 1 |
| Donati, M | 1 |
| Hahn-Zoric, M | 1 |
| Hanson, LA | 1 |
| Padyukov, L | 1 |
| Sahingur, SE | 1 |
| Sharma, A | 1 |
| Genco, RJ | 1 |
| De Nardin, E | 1 |
| Louie, M | 1 |
| Hogan, C | 1 |
| Hurley, A | 1 |
| Simon, V | 1 |
| Chung, C | 1 |
| Padte, N | 1 |
| Lamy, P | 1 |
| Flaherty, J | 1 |
| Coakley, D | 1 |
| Di Mascio, M | 1 |
| Perelson, AS | 1 |
| Markowitz, M | 1 |
| Fassmann, A | 1 |
| Holla, LI | 1 |
| Buckova, D | 1 |
| Vasku, A | 1 |
| Znojil, V | 1 |
| Vanek, J | 1 |
| Hoeger-Bement, MK | 1 |
| Sluka, KA | 1 |
| Scarel-Caminaga, RM | 1 |
| Trevilatto, PC | 1 |
| Souza, AP | 1 |
| Brito, RB | 1 |
| Camargo, LE | 1 |
| Line, SR | 2 |
| Folwaczny, M | 1 |
| Glas, J | 1 |
| Török, HP | 1 |
| Mende, M | 1 |
| Folwaczny, C | 1 |
| Van Rompay, KK | 1 |
| Singh, RP | 1 |
| Brignolo, LL | 1 |
| Lawson, JR | 1 |
| Schmidt, KA | 1 |
| Pahar, B | 1 |
| Canfield, DR | 1 |
| Tarara, RP | 1 |
| Sodora, DL | 1 |
| Bischofberger, N | 2 |
| Marthas, ML | 1 |
| Neff, GW | 1 |
| Nery, J | 1 |
| Lau, DT | 1 |
| O'Brien, CB | 1 |
| Duncan, R | 1 |
| Shire, NJ | 1 |
| Ruiz, P | 1 |
| Nery, C | 1 |
| Montalbano, M | 1 |
| Muslu, H | 1 |
| Safdar, K | 1 |
| Schiff, ER | 1 |
| Tzakis, AG | 1 |
| Madariaga, JR | 1 |
| Spinazzola, A | 1 |
| Carrara, F | 1 |
| Mora, M | 1 |
| Zeviani, M | 1 |
| Schildgen, O | 1 |
| Schewe, CK | 1 |
| Vogel, M | 1 |
| Däumer, M | 1 |
| Kaiser, R | 1 |
| Weitner, L | 1 |
| Matz, B | 1 |
| Rockstroh, JK | 1 |
| Maier, KP | 1 |
| Astolfi, CM | 1 |
| Shinohara, AL | 1 |
| da Silva, RA | 1 |
| Santos, MC | 1 |
| de Souza, AP | 1 |
| Metzner, KJ | 1 |
| Binley, JM | 1 |
| Gettie, A | 1 |
| Marx, P | 1 |
| Nixon, DF | 1 |
| Connor, RI | 1 |
| de Silva, TI | 1 |
| Post, FA | 1 |
| Griffin, MD | 1 |
| Dockrell, DH | 1 |
| Tsai, CC | 1 |
| Follis, KE | 1 |
| Sabo, A | 1 |
| Grant, R | 1 |
| Brand, K | 1 |
| Dugi, KA | 1 |
| Brunzell, JD | 1 |
| Nevin, DN | 1 |
| Santamarina-Fojo, S | 1 |
| Zimmerman, SA | 1 |
| Ware, RE | 1 |
| Forman, L | 1 |
| Westwood, B | 1 |
| Beutler, E | 1 |
| Gorry, MC | 1 |
| Gabbaizedeh, D | 1 |
| Furey, W | 1 |
| Gates, LK | 1 |
| Preston, RA | 1 |
| Aston, CE | 1 |
| Zhang, Y | 1 |
| Ulrich, C | 1 |
| Ehrlich, GD | 1 |
| Whitcomb, DC | 1 |
| Cullen, JM | 1 |
| Li, DH | 1 |
| Brown, C | 1 |
| Eisenberg, EJ | 1 |
| Cundy, KC | 1 |
| Wolfe, J | 1 |
| Toole, J | 1 |
| Gibbs, C | 1 |
| Korepanov, AM | 1 |
| Murashov, VS | 1 |
| Bazhenov, EL | 1 |
| Chlumský, J | 1 |
| Hyncík, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT03734016] | Phase 3 | 652 participants (Actual) | Interventional | 2018-11-01 | Active, not recruiting | ||
| A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)[NCT03474679] | Phase 3 | 19 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease[NCT02195869] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2014-07-14 | Completed | ||
| Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
| Efficacy and Safety of the Combination of Low-dose Ibrutinib and Itraconazole in Moderate to Severe Chronic Graft Versus Host Disease: a Phase 2 Trial[NCT05348096] | Phase 2 | 13 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655] | 684 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"ORR is the percentage of participants with PR or higher, (CR/CRi) + PR + nodular PR per IRC assessment using the modified 2008 IWCLL guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for NHL for participants with SLL" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zanubrutinib | 86.2 |
| Ibrutinib | 75.7 |
"ORR is percentage of participants with partial response (PR) or higher, (defined as Complete response/ Complete response with incomplete bone marrow recovery (CR/CRi) + PR + nodular PR) per investigator assessment using the modified 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for non-Hodgkin lymphoma (NHL)) for participants with Small lymphocytic lymphoma (SLL)" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zanubrutinib | 83.5 |
| Ibrutinib | 74.2 |
DOR is defined as the duration from the date of initial response (CR or PR) to the date of progressive cGVHD or death, whichever occurred first. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs. (NCT03474679)
Timeframe: Up to 3 year 6 months
| Intervention | Months (Median) |
|---|---|
| Ibrutinib 420 mg | NA |
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are adverse events with onset during the treatment phase or that were a consequence of a preexisting condition that has worsened since baseline, and occurred during treatment or within 30 days following the last dose of study treatment, or any adverse event that was considered study treatment-related regardless of the start date of the event. (NCT03474679)
Timeframe: Up to 3 year 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib 420 mg | 19 |
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death based on the National Institutes of Health (NIH) Consensus Development Project Criteria (2014). CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and chronic graft versus host disease (cGVHD) progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs. (NCT03474679)
Timeframe: Up to 3 year 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Ibrutinib 420 mg | 84.2 |
Percentage of participants with overall improvement in Lee cGVHD symptom scale score was reported. Lee cGVHD symptom scale is a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing a better outcome. A score was calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 with a higher score indicating worse symptoms. An overall score was calculated as the average of these 7 subscales if at least 4 subscales had valid scores. A change of greater than or equal to (>=) 7 points on the Lee cGVHD symptom scale overall score was considered significant and relates to improvement in quality of life (QoL). (NCT03474679)
Timeframe: Up to 3 year 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Ibrutinib 420 mg | 52.6 |
Sustained response rate was defined as percentage of participants with NIH defined CR or PR that was sustained for at least 20 weeks. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site. (NCT03474679)
Timeframe: Up to 3 year 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Ibrutinib 420 mg | 68.8 |
CL/F is defined as apparent clearance of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | Milliliters per hour (mL/h) (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 194211 | 162457 |
CL/F is defined as apparent clearance of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | mL/h (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 251681 | 111922 |
Vd/F is defined as apparent volume of distribution of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | Milliliters (mL) (Mean) |
|---|---|
| Week 1: Day 1 | |
| Ibrutinib 420 mg | 1350160 |
Vd/F is defined as apparent volume of distribution of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | mL (Mean) |
|---|---|
| Week 1: Day 1 | |
| Ibrutinib 420 mg | 2148283 |
AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of ibrutinib. (NCT03474679)
Timeframe: 0 to 24 hours (Day 1 of Weeks 1 and 2)
| Intervention | hour*ng/mL (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 2929.3 | 4035.6 |
AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of PCI-45227. (NCT03474679)
Timeframe: 0 to 24 hours (Day 1 of Weeks 1 and 2)
| Intervention | hour*ng/mL (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 1803.0 | 2547.6 |
AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | hour*ng/mL (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 2643.8 | 2659.2 |
AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | hour*ng/mL (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 1766.1 | 3752.6 |
AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | hours*nanograms per milliliter (h*ng/mL) (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 3683.7 | 4024.8 |
AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | h*ng/mL (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 1976.9 | 2547.6 |
cGVHD response rate was defined as percentage of participants with NIH defined CR or PR at each timepoint. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site. (NCT03474679)
Timeframe: Weeks 5, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 5 | Week 13 | Week 25 | Week 37 | Week 49 | Week 61 | Week 73 | Week 85 | Week 97 | Week 109 | Week 121 | Week 133 | Week 145 | Week 157 | |
| Ibrutinib 420 mg | 26.3 | 42.1 | 52.6 | 47.4 | 47.4 | 42.1 | 36.8 | 31.6 | 31.6 | 31.6 | 36.8 | 31.6 | 26.3 | 10.5 |
Change in the amount of corticosteroid required over time was reported. (NCT03474679)
Timeframe: Baseline, Weeks 24, 48, 96, and 144
| Intervention | Milligrams per kilograms per day (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Week 24 | Week 48 | Week 96 | Week 144 | |
| Ibrutinib 420 mg | 0.270 | 0.250 | 0.150 | 0.140 | 0.140 |
T1/2 is defined as elimination half-life of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | Hours (Median) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 4.9 | 4.4 |
T1/2 is defined as elimination half-life of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | Hours (Median) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 5.9 | 5.4 |
Cmax is defined as maximum observed plasma concentration of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | Nanograms per milliliter (ng/mL) (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 490.45 | 478.01 |
Cmax is defined as maximum observed plasma concentration of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 185.37 | 203.16 |
Tmax is defined as time to reach the maximum observed plasma concentration of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | Hours (Median) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 3.87 | 4.02 |
Tmax is defined as time to reach the maximum observed plasma concentration of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2
| Intervention | Hours (Median) | |
|---|---|---|
| Week 1: Day 1 | Week 2: Day 1 | |
| Ibrutinib 420 mg | 4.00 | 4.02 |
"Subject reported improvement in symptom burden. The symptom burden will be measured according to the Lee cGVHD Symptom Scale. A change in >7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life.~A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. A total summary score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.~There are 7 subscales (Skin, Energy, Lung, Eye, Nutrition, Mouth and Psychological) with ratings as follow: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely; with a lower values representing a better outcome." (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 1b/Phase 2 | 42.9 |
Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib (NCT02195869)
Timeframe: 28 treatment days after last subject enrolled in Phase 1 dose level(s).
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1b: Dose Level 1 | 0 |
Overall Response Rate is defined as the proportion of subjects who achieved complete response (CR) or partial response (PR). Response criteria are based on NIH cGVHD Response assessment (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site). (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase1b/Phase 2 | 69 |
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib (NCT02195869)
Timeframe: From first dose with study drug until 30 days after the last dose of study drug, up to 36.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1b/Phase 2 | 42 |
For subjects who achieved an NIH-defined CR or PR, the proportion of subjects who achieved CR or PR that was sustained for at least 20 weeks (140 days). Intermittent SD was also acceptable. (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase1b/Phase 2 | 69 |
For subjects who achieved an NIH-defined CR or PR, the interval between the date of initial documentation of a response and the date of first documented evidence of PD, death, or date of censoring if applicable. (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
| Intervention | Median (Median) |
|---|---|
| Phase1b/Phase 2 | NA |
Average daily corticosteroid dose assessed each week. (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.
| Intervention | Daily Dose of Steroid by Weight (mg/kg/d (Median) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | Week 19 | Week 20 | Week 21 | Week 22 | Week 23 | Week 24 | Week 25 | Week 26 | Week 27 | Week 28 | Week 29 | Week 30 | Week 31 | Week 32 | Week 33 | Week 34 | Week 35 | Week 36 | Week 37 | Week 38 | Week 39 | Week 40 | Week 41 | Week 42 | Week 43 | Week 44 | Week 45 | Week 46 | Week 47 | Week 48 | Week 49 | Week 50 | Week 51 | Week 52 | Week 53 | Week 54 | Week 55 | Week 56 | Week 57 | Week 58 | Week 59 | Week 60 | Week 61 | Week 62 | Week 63 | Week 64 | Week 65 | Week 66 | Week 67 | Week 68 | Week 69 | Week 70 | Week 71 | Week 72 | Week 73 | Week 74 | Week 75 | Week 76 | Week 77 | Week 78 | Week 79 | Week 80 | Week 81 | Week 82 | Week 83 | Week 84 | Week 85 | Week 86 | Week 87 | Week 88 | Week 89 | Week 90 | Week 91 | Week 92 | Week 93 | Week 94 | Week 95 | Week 96 | Week 97 | Week 98 | Week 99 | Week 100 | Week 101 | Week 102 | Week 103 | Week 104 | Week 105 | Week 106 | Week 107 | Week 108 | Week 109 | Week 110 | Week 111 | Week 112 | Week 113 | Week 114 | Week 115 | Week 116 | Week 117 | Week 118 | Week 119 | Week 120 | Week 121 | Week 122 | Week 123 | Week 124 | Week 125 | Week 126 | Week 127 | Week 128 | Week 129 | Week 130 | Week 131 | Week 132 | Week 133 | Week 134 | Week 135 | Week 136 | Week 137 | Week 138 | Week 139 | Week 140 | Week 141 | Week 142 | Week 143 | Week 144 | Week 145 | Week 146 | Week 147 | Week 148 | Week 149 | Week 150 | Week 151 | Week 152 | Week 153 | Week 154 | Week 155 | Week 156 | Week 157 | Week 158 | Week 159 | Week 160 | |
| Phase 1b/Phase 2 | 0.31 | 0.32 | 0.32 | 0.31 | 0.31 | 0.30 | 0.30 | 0.30 | 0.27 | 0.25 | 0.25 | 0.25 | 0.24 | 0.23 | 0.23 | 0.23 | 0.21 | 0.20 | 0.20 | 0.21 | 0.22 | 0.22 | 0.22 | 0.21 | 0.19 | 0.18 | 0.18 | 0.18 | 0.16 | 0.16 | 0.16 | 0.18 | 0.17 | 0.17 | 0.18 | 0.18 | 0.16 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.12 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.12 | 0.12 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.12 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.06 | 0.06 |
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib Plus Rituximab | 0 |
7 reviews available for adenine and Chronic Illness
| Article | Year |
|---|---|
Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Topics: Adenine; Adrenal Cortex Hormones; Chronic Disease; Cyclophosphamide; Graft vs Host Disease; Hematopo | 2020 |
Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease.
Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; My | 2021 |
Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
Topics: Adenine; Animals; Chronic Disease; Drug Interactions; Graft vs Host Disease; Humans; Piperidines; Py | 2018 |
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Topics: Adenine; Animals; B-Lymphocytes; Chronic Disease; Drug Approval; Drug Resistance; Graft vs Host Dise | 2018 |
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic | 2012 |
[Drug therapy in chronic liver disease].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Scleros | 2005 |
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enz | 2007 |
5 trials available for adenine and Chronic Illness
| Article | Year |
|---|---|
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chronic Disease; Clinical Trials, Phase III as Topic; | 2020 |
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles; | 2021 |
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles; | 2021 |
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles; | 2021 |
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles; | 2021 |
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro | 2017 |
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro | 2017 |
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro | 2017 |
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro | 2017 |
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim | 2019 |
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim | 2019 |
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim | 2019 |
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim | 2019 |
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Chronic Disease; Female; HIV Infections; HIV-1; Humans; Male; Middl | 2003 |
40 other studies available for adenine and Chronic Illness
| Article | Year |
|---|---|
Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection.
Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; My | 2021 |
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
Topics: Adenine; Aged; Alemtuzumab; Antineoplastic Agents, Immunological; Antiviral Agents; Chronic Disease; | 2019 |
Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
Topics: Adenine; Adult; Austria; Bronchiolitis Obliterans; Chronic Disease; Female; Germany; Graft vs Host D | 2019 |
Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy.
Topics: Adenine; Animals; Arachidonate 12-Lipoxygenase; Blotting, Western; Catalase; Chronic Disease; Cycloo | 2013 |
Expression and function of methylthioadenosine phosphorylase in chronic liver disease.
Topics: Adenine; Animals; Apoptosis; Chronic Disease; Gene Expression Regulation; Hepatic Stellate Cells; He | 2013 |
Ibrutinib monotherapy in chronic lymphoid leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2014 |
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Chronic Disease; Disease Progression; Factor Analysis, | 2015 |
The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia.
Topics: Acute Kidney Injury; Adenine; Animals; Chronic Disease; Disease Models, Animal; Fibroblast Growth Fa | 2016 |
Continuous single motor unit electromyographic activity in adefovir associated myopathy.
Topics: Adenine; Antiviral Agents; Chronic Disease; Creatine Kinase; Electromyography; Hepatitis B; Humans; | 2008 |
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Mode | 2009 |
Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
Topics: Adenine; Animals; Aortic Diseases; Biomarkers; Blood Urea Nitrogen; Calcinosis; Calcium; Calcium Car | 2009 |
Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease.
Topics: Adenine; Animals; Chronic Disease; Down-Regulation; Fibroblast Growth Factor-23; Fibroblast Growth F | 2010 |
Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications.
Topics: Adenine; Animals; Calcium Metabolism Disorders; Chronic Disease; Male; Rats; Rats, Inbred F344; Rena | 2010 |
Effects of Gum Arabic in rats with adenine-induced chronic renal failure.
Topics: Adenine; Animals; Anti-Inflammatory Agents; Antioxidants; Chronic Disease; Disease Models, Animal; D | 2010 |
The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors.
Topics: Adenine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blotting, Western; Body Weigh | 2010 |
Chronic kidney disease aggravates arteriovenous fistula damage in rats.
Topics: Adenine; Animals; Arteriovenous Shunt, Surgical; Blood Pressure; Calcinosis; Chronic Disease; Constr | 2010 |
Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.
Topics: Adenine; Adult; Chronic Disease; Female; Graft vs Host Disease; Hepatitis B virus; Hepatitis B, Chro | 2011 |
Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Biopsy; Chronic Disease | 2011 |
Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
Topics: Adenine; Animals; Cells, Cultured; Chronic Disease; Class Ia Phosphatidylinositol 3-Kinase; Female; | 2012 |
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-D | 2012 |
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Chronic Disease; HIV Infections; Humans; Kidne | 2002 |
Association of the -1087 IL 10 gene polymorphism with severe chronic periodontitis in Swedish Caucasians.
Topics: Adenine; Adult; Aged; Alleles; Alveolar Bone Loss; Chi-Square Distribution; Chronic Disease; Confide | 2003 |
Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis.
Topics: 5' Flanking Region; Adenine; Age Factors; Aged; Alleles; Analysis of Variance; Case-Control Studies; | 2003 |
Polymorphisms in the +252(A/G) lymphotoxin-alpha and the -308(A/G) tumor necrosis factor-alpha genes and susceptibility to chronic periodontitis in a Czech population.
Topics: Adenine; Adult; Case-Control Studies; Chronic Disease; Czech Republic; Female; Gene Frequency; Genet | 2003 |
Phosphorylation of CREB and mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections.
Topics: Acids; Adenine; Adenylyl Cyclase Inhibitors; Animals; Behavior, Animal; Chronic Disease; Cyclic AMP; | 2003 |
Interleukin 10 gene promoter polymorphisms are associated with chronic periodontitis.
Topics: Adenine; Adult; Chronic Disease; Cytosine; Female; Gene Frequency; Genetic Predisposition to Disease | 2004 |
Lack of association between the TNF alpha G -308 A promoter polymorphism and periodontal disease.
Topics: Adenine; Adult; Aged; Alleles; Chronic Disease; Female; Gene Frequency; Genetic Predisposition to Di | 2004 |
The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; CD4-Positive T-Lymphocytes; | 2004 |
Tenofovir therapy for lamivudine resistance following liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B, | 2004 |
Mitochondrial myopathy and ophthalmoplegia in a sporadic patient with the 5698G-->A mitochondrial DNA mutation.
Topics: Adenine; Aged; Base Sequence; Chronic Disease; DNA, Mitochondrial; Electron Transport Complex IV; Gu | 2004 |
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directe | 2004 |
Genetic polymorphisms in the MMP-1 and MMP-3 gene may contribute to chronic periodontitis in a Brazilian population.
Topics: Adenine; Adult; Alleles; Brazil; Chronic Disease; Female; Gene Frequency; Genetic Predisposition to | 2006 |
Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; CD8-Positive T-Lymphocytes; Chronic Disease; D | 2006 |
Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques.
Topics: Adenine; Animals; Antiviral Agents; Chronic Disease; DNA, Viral; Leukocytes, Mononuclear; Lymphocyte | 1995 |
A novel A-->G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency.
Topics: Adenine; Alternative Splicing; Amino Acid Sequence; Base Sequence; Child; Chronic Disease; DNA Prime | 1996 |
Glucose-6-phosphate dehydrogenase Durham: a de novo mutation associated with chronic hemolytic anemia.
Topics: Adenine; Amino Acid Sequence; Anemia, Hemolytic, Congenital Nonspherocytic; Arginine; Base Sequence; | 1997 |
Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis.
Topics: Acute Disease; Adenine; Asparagine; Chromosome Mapping; Chromosomes, Human, Pair 7; Chronic Disease; | 1997 |
Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.
Topics: Adenine; Administration, Oral; Animals; Chemistry, Clinical; Chronic Disease; Disease Models, Animal | 2001 |
[The dynamics of the indices of protein metabolic homeostasis and the status of duodenal mucosal regeneration during the etaden treatment of duodenal peptic ulcer].
Topics: Adenine; Adolescent; Adult; Anti-Ulcer Agents; Chronic Disease; Drug Evaluation; Duodenal Ulcer; Duo | 1992 |
[Problem of active therapeutic procedure in chronic liver disease].
Topics: Adenine; Adult; Aged; Chronic Disease; Diet Therapy; Female; Humans; Inositol; Liver Diseases; Male; | 1972 |